Preclinical Evidence for Targeting PI3K/mTOR Signaling with Dual-Inhibitors as a Therapeutic Strategy against...

Area of Science:

• Oncology
• Molecular Biology
• Dermatology

Background:

• The phosphoinositide 3-kinase (PI3K)/protein kinase B (AKT)/mammalian target of rapamycin (mTOR) pathway is frequently hyperactivated in various cancers, including cutaneous T-cell lymphoma (CTCL).
• Specific subtypes of CTCL, mycosis fungoides and Sezary syndrome (SS), exhibit elevated TORC1 signaling driven by overexpressed cytokines and chemokines.
• Genetic alterations in key pathway genes like PTEN, LKB1, and P70S6K contribute to pathway hyperactivation in CTCL.

Purpose of the Study:

• To evaluate the therapeutic efficacy of mTOR inhibitors in cutaneous T-cell lymphoma (CTCL).
• To compare the effectiveness of rapalogs and a dual PI3K/mTOR inhibitor in CTCL models.

Main Methods:

• Screening of four CTCL cell lines using three rapalogs (rapamycin, temsirolimus, everolimus) and a dual PI3K/mTOR inhibitor (PF-04691502).
• Assessment of antitumor activity in patient-derived CTCL cells and a xenograft mouse model.
• Analysis of PTEN gene expression in relation to drug response.

Main Results:

• The dual PI3K/mTOR inhibitor PF-04691502 demonstrated superior inhibition of cell growth compared to rapalogs.
• PF-04691502 exhibited significant antitumor effects, including apoptosis induction and increased survival, in patient-derived cells and a mouse model.
• An inverse correlation was observed between PTEN gene expression and PF-04691502's apoptotic efficacy in SS cells.

Conclusions:

• Dual PI3K/mTOR inhibitors, particularly PF-04691502, represent a promising therapeutic strategy for CTCL.
• PTEN expression levels may predict response to dual PI3K/mTOR inhibition in SS.
• Further investigation into dual PI3K/mTOR inhibitors is warranted for CTCL treatment.